International Journal of Drug Delivery Technology
Volume 14, Issue 4

Enhanced Oral Absorption and Bioavailability of Ivermectin Through Amorphous Solid Dispersion Techniques

Chang Y*, Li J, Zou Z Z*

Department of DMPK&TOX, Global Health Drug Discovery Institute,Unit 2-B, Zhongguancun Dongsheng International Science Park, 1 North Yongtaizhuang Road, Beijing 100192, China 

Received: 21st Jun 2024; Revised: 23rd Oct, 2024; Accepted: 14th Nov, 2024; Available Online: 25th Dec, 2024 

ABSTRACT

The purpose of this study was to develop a high-loading amorphous solid dispersion (ASD) of ivermectin to significantly enhance its oral absorption and bioavailability. Using a solvent method, we formulated a novel ternary ASD with polyvinylpyrrolidone PVPK30 and Poloxamer 188 (P188) in a 1:0.5:1.5 ratio of drug to PVPK30 to P188. We characterized the physicochemical properties of five ASD formulations through in vitro dissolution tests. The selected formulation, SD3, was further assessed using X-ray powder diffraction, scanning electron microscopy, differential scanning calorimetry, and pharmacokinetic studies in rats. Notably, SD3 enhanced drug loading more than 30-fold compared to commercial tablets. SD3 exhibited significantly faster dissolution rates and maintained an amorphous state that remained stable after two months of storage at 4°C. Pharmacokinetic analysis at a 20 mg/kg oral dose in rats showed that SD3 achieved the highest maximum concentration (Cmax), plasma exposure (AUC), and oral bioavailability compared to the pure drug and commercial tablets. The assessment of the oral absorption rate constant (Ka) revealed an increased Ka and intestinal permeability through this ASD, elucidating the possible mechanism behind these improvements.

Keywords: Ivermectin; Amorphous solid dispersion; Dissolution; Bioavailability.

How to cite this article: Chang Y, Li J, Zou Z Z. Enhanced Oral Absorption and Bioavailability of Ivermectin Through Amorphous Solid Dispersion Techniques. International Journal of Drug Delivery Technology. 2024;14(4):2013-22 . doi: 10.25258/ijddt.14.4.10

REFERENCES

  1. Dourmishev AL, Dourmishev LA and Schwartz RA. Ivermectin: pharmacology and application in dermatology. Int J Dermatol 2005; 44: 981-988. 2006/01/18. DOI: 10.1111/j.1365-4632.2004.02253.x.
  2. Ashour DS. Ivermectin: From theory to clinical application. Int J Antimicrob Agents 2019; 54: 134-142. 2019/05/10. DOI: 10.1016/j.ijantimicag.2019.05.003.
  3. Caly L, Druce JD, Catton MG, et The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res 2020; 178: 104787. 2020/04/07. DOI: 10.1016/j.antiviral.2020.104787.
  4. Ooi Repurposing ivermectin as an anti-dengue drug. Oxford University Press US, 2021, p. e594-e595.
  5. Wagstaff KM, Sivakumaran H, Heaton SM, et al. Ivermectin is a specific inhibitor of importin α/β- mediated nuclear import able to inhibit replication of HIV-1 and dengue virus. Biochemical Journal 2012; 443: 851-856.
  6. Krolewiecki A, Lifschitz A, Moragas M, et al. Corrigendum to Antiviral effect of high-dose ivermectin in adults with COVID-19: A proof-of-concept randomized trial  [EClinicalMedicine  37  (2021)100,959]". EClinicalMedicine 2021; 39: 101119. 2021/09/01. DOI: 10.1016/j.eclinm.2021.101119.
  7. Krolewiecki A, Lifschitz A, Moragas M, et al. Antiviral effect of high-dose ivermectin in adults with COVID-19: A proof-of-concept  randomized                   EClinicalMedicine 2021; 37: 100959. 2021/07/01. DOI: 10.1016/j.eclinm.2021.100959.
  8. Tan X, Xie H, Zhang B, et al. A Novel Ivermectin- Derived Compound D4 and Its Antimicrobial/Biofilm Properties against MRSA. Antibiotics (Basel) 2021; 10 2021/03/07. DOI: 10.3390/antibiotics10020208.
  9. Tang M, Hu X, Wang Y, et al. Ivermectin, a potential anticancer drug derived from an antiparasitic drug. Pharmacol Res 2021; 163: 105207. 2020/09/25. DOI: 1016/j.phrs.2020.105207.
  10. Crump Ivermectin: enigmatic multifaceted 'wonder' drug continues to surprise and exceed expectations. J Antibiot (Tokyo) 2017; 70: 495-505. 2017/02/16. DOI: 10.1038/ja.2017.11.
  11. Lindenberg M, Kopp S and Dressman Classification of orally administered drugs on the World Health Organization Model list of Essential Medicines according to the biopharmaceutics classification system. Eur J Pharm Biopharm 2004; 58: 265-278. 2004/08/07. DOI: 10.1016/j.ejpb.2004.03.001.
  12. Marchenko VA, Khalikov SS, Efremova EA, et al. Efficacy of Novel Formulations of Ivermectin and Albendazole in Parasitic Infections of Sheep in the Altai Mountains of Russia. Iran J Parasitol 2021; 16: 199-2021/09/25. DOI: 10.18502/ijpa.v16i2.6268.
  13. Singh D and Pathak K. Hydrogen bond replacement-- unearthing a novel molecular mechanism of surface solid dispersion for enhanced solubility of a drug for veterinary use. Int J Pharm 2013; 441: 99-110. 2012/12/25. DOI: 10.1016/j.ijpharm.2012.12.008.
  14. Verma S, Patel U and Patel RP. Formulation and evaluation of ivermectin solid dispersion. Journal of Drug Delivery and Therapeutics 2017; 7: 15-17.
  15. Starkloff WJ, Bucala V, Palma SD, et al. Design and in vitro characterization of ivermectin nanocrystals liquid formulation based on a top-down Pharm Dev Technol 2017; 22: 809-817. 2016/06/28. DOI: 10.1080/10837450.2016.1200078.
  16. Das S, Lee SH, Chia VD, et al. Development of microemulsion based topical ivermectin formulations: Pre-formulation and formulation studies. Colloids SurfB Biointerfaces 2020; 189: 110823. 2020/02/10. DOI: 1016/j.colsurfb.2020.110823.
  17. Guo D, Dou D, Li X, et al. Ivermection-loaded solid lipid nanoparticles: preparation, characterisation, stability and transdermal behaviour. Artif Cells Nanomed Biotechnol 2018; 46: 255-262. 2017/04/04. DOI: 10.1080/21691401.2017.1307207.
  18. Dong J, Song X, Lian X, et Subcutaneously injected ivermectin-loaded mixed micelles: formulation, pharmacokinetics and local irritation study. Drug Deliv 2016; 23: 2220-2227.  2016/10/18.  DOI:10.3109/10717544.2014.956849.
  19. Mansour SM, Shamma RN, Ahmed KA, et Safety of inhaled ivermectin as a repurposed direct drug for treatment of COVID-19: A preclinical tolerance study. International Immunopharmacology 2021; 99: 108004.
  20. Patel VP, Lakkad HA and Ashara KC. Formulation Studies of Solid Self-Emulsifying Drug Delivery System of Ivermectin. Folia Med (Plovdiv) 2018; 60: 580-593. 2019/06/13. DOI: 2478/folmed-2018-0024.
  21. Rolim LA, dos Santos FCM, Chaves LL, et al. Preformulation study of ivermectin raw material. Journal of Thermal Analysis and Calorimetry 2015; 120: 807-816.
  22. Damian F, Blaton N, Naesens L, et Physicochemical characterization of solid dispersions of the antiviral agent UC-781 with polyethylene glycol 6000 and Gelucire 44/14. Eur J Pharm Sci 2000; 10: 311-322. 2000/06/06. DOI: 10.1016/s0928-0987(00)00084-1.
  23. de Oliveira Eloy J, Saraiva J, de Albuquerque S, et al. Solid dispersion of ursolic acid in Gelucire 50/13: a strategy to enhance drug release and trypanocidal activity. AAPS PharmSciTech 2012; 13: 1436-1445. 2012/10/17. DOI: 10.1208/s12249-012-9868-2.
  24. Smith Selective solubility:" Like dissolves like".Journal of Chemical Education 1977; 54: 228.
  25. Zhuang B, Ramanauskaite G, Koa ZY, et al. Like dissolves like: A first-principles theory for predicting liquid miscibility and mixture dielectric constant. Sci Adv 2021; 7 2021/02/14. DOI: 1126/sciadv.abe7275.
  26. Newman A, Engers D, Bates S, et al. Characterization of amorphous API:Polymer mixtures using X-ray powder diffraction. J Pharm Sci 2008; 97: 4840-4856. 2008/03/21. DOI: 10.1002/jps.21352.
  27. Budiman A, Lailasari E, Nurani NV, et Ternary Solid Dispersions: A Review of the Preparation, Characterization, Mechanism of Drug Release, and Physical Stability. Pharmaceutics 2023; 15 2023/08/26. DOI: 10.3390/pharmaceutics15082116.
  28. Jafar M, Salahuddin M, Kayed M, et al. Solid state analysis and in-vitro dissolution behavior of meloxicam-hydroxy propyl beta cyclodextrin- ethanolamines ternary complexes. International Journal of Pharmaceutical Quality Assurance 2018; 9: 298-304. DOI: 10.25258/ijpqa.v9i01.11919.
  29. Wagh VT, Gilhotra RM and Wagh Solid dispersion (Kneading) technique: a platform for enhancement dissolution rate of valsartan poorly water-soluble drug. International Journal of Pharmaceutical Quality Assurance 2020; 11: 20-24.
  30. Fo’ad T, Hameed GS and Raauf Thermal Analysis in the Pre-formulation of Amorphous Solid Dispersion for Poorly Water-soluble Drugs. International Journal of Drug Delivery Technology 2022; 12: 1595-1599. DOI: 10.25258/ijddt.12.4.19.
  31. Anjana R, Kumar S, Sharma H, et al. Phytosome drug delivery of natural products: A promising technique for enhancing bioavailability. International Journal of Drug Delivery Technology 2017; 7: 157-165.
  32. Frizon F, de Oliveira Eloy J, Donaduzzi CM, et al. Dissolution rate enhancement of loratadine in polyvinylpyrrolidone K-30 solid dispersions by solvent methods. Powder technology 2013; 235: 532-539.
  33. Szafraniec J, Antosik A, Knapik-Kowalczuk J, et al. Molecular disorder of bicalutamide—amorphous solid dispersions obtained by solvent methods. Pharmaceutics 2018; 10: 194.
  34. Tayyab Ansari M, Arshad MS, Hussain A, et al. Improvement of solubility, dissolution and stability profile of artemether solid dispersions and self emulsified solid dispersions by solvent evaporation method. Pharm Dev Technol 2018; 23: 1007-1015. 2016/11/26. DOI: 10.1080/10837450.2016.1265554.
  35. Hadi AS and Ghareeb MM. Rizatriptan benzoate nanoemulsion for intranasal drug delivery: preparation and characterization. International Journal of Drug Delivery Technology 2022; 12: 546-552.
  36. Omar TN, Mahdi MF, Al-Mudhafar MMJ, et al. Synthesize of New Ibuprofen and Naproxen Sulphonamide Conjugate with Anti-Inflammatory Study and Molecular Docking Study. International Journal of Pharmaceutical Quality Assurance 2018; 9: 102-108.
  37. Newa M, Bhandari KH, Li DX, et al. Preparation, characterization and in vivo evaluation of ibuprofen binary solid dispersions with poloxamer 188. Int J Pharm 2007; 343: 228-237. 2007/06/29. DOI: 1016/j.ijpharm.2007.05.031.
  38. Chokshi RJ, Zia H, Sandhu HK, et al. Improving the dissolution rate of poorly water soluble drug by solid dispersion and solid solution: pros and Drug Deliv 2007; 14: 33-45.   2006/11/17.   DOI:10.1080/10717540600640278.
  39. Sharma A and Jain Preparation and characterization of solid dispersions of carvedilol with PVP K30. Res Pharm Sci 2010; 5: 49-56. 2010/01/01.
  40. Kadhim ZJ and Rajab NA. Formulation and characterization of glibenclamide nanoparticles as an oral film. International Journal of Drug Delivery Technology 2022; 12: 387-394.
  41. Chen ML, Lesko L and Williams RL. Measures of exposure versus measures of rate and extent of absorption. Clin Pharmacokinet 2001; 40: 565-572. 2001/08/29. DOI: 2165/00003088-200140080-00001.
  42. Zhao L, Shi X and Zhang J. The Simulation of the relevance of absorption rate constant and elimination rate constant to the plasma drug In: 2012 International Conference on Computer Science and Electronics Engineering 2012, pp.420-424. IEEE.
  43. Rathod S, Desai H, Patil R, et Non-ionic surfactants as a P-glycoprotein (P-gp) efflux inhibitor for optimal drug delivery—a concise outlook. Aaps Pharmscitech 2022; 23: 55.
  44. Lespine A, Martin S, Dupuy J, et al. Interaction of macrocyclic lactones with P-glycoprotein: structure- affinity relationship. Eur J Pharm Sci 2007; 30: 84-94. 2006/12/01. DOI: 10.1016/j.ejps.2006.10.004.Li Y, Li J, Zhang X, et Non-ionic surfactants as novel intranasal absorption enhancers: in vitro and in vivo characterization. Drug delivery 2016; 23: 2272-2279.
  45. Qin X, Yuan F, Zhou D, et al. Oral characteristics of bergenin and the effect of absorption enhancers in situ, in vitro and in vivo. Arzneimittelforschung 2010; 60: 198-204. 2010/05/22. DOI: 10.1055/s-0031-1296273.